AI Article Synopsis
- This study explores how Graves' orbitopathy (GO) is managed across 26 medical centers in France, focusing on the structure and availability of treatment services.
- Researchers contacted 28 centers to gather data through a questionnaire about multidisciplinary meetings, dedicated services, and treatment methods.
- The findings revealed that while a majority have dedicated services and utilize first-line treatments like intravenous corticosteroids, there’s significant variability in practices, highlighting the need for standardization and improving accessibility to new treatments like tocilizumab and teprotumumab.
Article Abstract
Introduction: This study investigates the management of Graves'orbitopathy (GO) in France, at 26 university medical centers (CHU) as well as the Rothschild Foundation and the Quinze-Vingts national eye hospital in Paris.
Methods: The 28 metropolitan university medical centers were contacted by telephone or e-mail. The authors devised a 5-item questionnaire that explored the scheduling of multidisciplinary meetings, the existence or lack of a dedicated Graves' consultation service, the place of hospitalization, and first- and second-line treatments.
Results: Eighty-nine percent of hospital departments had a dedicated service for patients with GO, with 36% organizing multidisciplinary meetings. Intravenous corticosteroid therapy is still used as first-line treatment, while mycophenolate is used much less (14.3%), despite the new EUGOGO (European Group on Graves' orbitopathy) 2021 recommendations. For second-line treatment, tocilizumab is most commonly used (64%). Teprotumumab is available in France only on a compassionate basis, and its use is limited (18%).
Conclusion: This study highlights the variability in practices and the importance of a multidisciplinary approach, while calling for national standardization of practices. Despite disparities in the application of recommendations, the emergence of second-line treatments such as tocilizumab and teprotumumab indicates a steady evolution in therapeutic options, although obstacles in terms of accessibility and cost remain.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jfo.2024.104301 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Elimination of oral foci of infection might lead to clinical improvement of Graves' orbitopathy.
Graefes Arch Clin Exp Ophthalmol
January 2025
Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355, Poznan, Poland.
Purpose: Graves' disease (GD) and Graves' orbitopathy (GO) are multifactorial disorders with links to the gut microbiome and autoimmunity. It is observed that patients with GD exhibit altered gut microbiome diversity. However, little is known about the role of oral microbiota in GD and GO.
View Article and Find Full Text PDFAssociation of obesity with orbital fat expansion in thyroid eye disease.
BMC Ophthalmol
January 2025
Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No. 138, Sheng Li Road, Tainan, 704, Taiwan.
Background: To investigate the association between obesity and orbital fat expansion in proptosis of thyroid eye disease.
Methods: This observational study retrospectively enrolled 87 participants who received orbital fat decompression surgery for thyroid eye disease. Primary outcome measures included average body mass index (BMI) and the proportion of the study sample with overweight and obesity, compared with the general Taiwanese population.
Effects of linsitinib on M22 and IGF:1-treated 3D spheroids of human orbital fibroblasts.
Sci Rep
January 2025
Departments of Ophthalmology, Sapporo Medical University School of Medicine, S-1 W-16, Chuo-Ku, Sapporo, 060-8543, Japan.
To elucidate the role of IGF1R inhibition in the pathogenesis of Graves' orbitopathy (GO), the effects of linsitinib (Lins) on a recombinant human TSHR antibody (M22) and IGF1 to activate TSHR and IGF1R of human orbital fibroblasts (HOFs) obtained from patients without GO (HOFs) and patients with GO (GHOFs) were studied using in vitro three-dimensional (3D) spheroid models in addition to their 2D planar cell culture. For this purpose, we evaluated 1) cellular metabolic functions by using a seahorse bioanalyzer (2D), 2) physical properties including size and stiffness of 3D spheroids, and mRNA expression of several extracellular matrix (ECM) proteins, their modulators (CCL2 LOX, CTGF, MMPs), ACTA2 and inflammatory cytokines (IL1β, IL6). Administration of IGF1 and M22 induced increases of cellular metabolic functions with the effect on HOFs being much more potent than the effect on GHOFs, suggesting that IGF1R and TSHR of GHOFs may already be stimulated.
View Article and Find Full Text PDFStimulation of Piezo1 mechanosensitive channels inhibits adipogenesis in thyroid eye disease.
J Clin Endocrinol Metab
January 2025
Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, Address: Hungary, 4032 Debrecen Nagyerdei krt. 98. Tel. +36-52-255-600.
Context: Increased orbital tissue volume due to matrix expansion, orbital fibroblast (OF) proliferation and adipocyte differentiation are the hallmarks of thyroid eye disease (TED). Their combination with the presence of hyaluronan-bound excess water in the constrains of the bony orbit results in increased intraorbital pressure. High intraorbital pressure, along with changes in the mechanical properties of orbital tissues, may lead to the activation of mechanosensitive receptors.
View Article and Find Full Text PDFIdentification and verification of the optimal feature genes of ferroptosis in thyroid-associated orbitopathy.
Front Immunol
December 2024
School of Optometry, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Background: Thyroid-associated orbitopathy (TAO) is an autoimmune inflammatory disorder of the orbital adipose tissue, primarily causing oxidative stress injury and tissue remodeling in the orbital connective tissue. Ferroptosis is a form of programmed cell death driven by the accumulation of reactive oxygen species (ROS), iron metabolism disorder, and lipid peroxidation. This study aims to identify and validate the optimal feature genes (OFGs) of ferroptosis with diagnostic and therapeutic potential in TAO orbital adipose tissue through bioinformatics analysis and to assess their correlation with disease-related immune cell infiltration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!